This review is a summary of a recent speaker event held in Sydney featuring Assistant Professor Jeffrey Sobell and titled, ‘Revealing guselkumab: the first interleukin-23 inhibitor for moderate-to-severe plaque psoriasis'.
A/P Sobell is Assistant Professor of Dermatology at Tufts University School of Medicine and, amongst other things, Director of the Psoriasis Treatment Center at SkinCare Physicians in Chestnut Hill, MA, USA.
Please login below to download this issue (PDF)